DE69929074D1 - Verwendung von einem rb2/p130 exprimierenden vektor zur verhinderung oder behandlung von restenose oder atherosklerotischen ablagerungen - Google Patents

Verwendung von einem rb2/p130 exprimierenden vektor zur verhinderung oder behandlung von restenose oder atherosklerotischen ablagerungen

Info

Publication number
DE69929074D1
DE69929074D1 DE69929074T DE69929074T DE69929074D1 DE 69929074 D1 DE69929074 D1 DE 69929074D1 DE 69929074 T DE69929074 T DE 69929074T DE 69929074 T DE69929074 T DE 69929074T DE 69929074 D1 DE69929074 D1 DE 69929074D1
Authority
DE
Germany
Prior art keywords
restenosis
prevention
treatment
atherosclerotic deposits
expressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69929074T
Other languages
English (en)
Other versions
DE69929074T2 (de
Inventor
Antonio Giordano
P Claudio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Application granted granted Critical
Publication of DE69929074D1 publication Critical patent/DE69929074D1/de
Publication of DE69929074T2 publication Critical patent/DE69929074T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69929074T 1998-09-11 1999-09-10 Verwendung von einem rb2/p130 exprimierenden vektor zur verhinderung oder behandlung von restenose oder atherosklerotischen ablagerungen Expired - Fee Related DE69929074T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9989698P 1998-09-11 1998-09-11
US99896P 1998-09-11
PCT/US1999/020723 WO2000015649A1 (en) 1998-09-11 1999-09-10 METHODS OF INHIBITING SMOOTH MUSCLE CELL PROLIFERATION AND PREVENTING RESTENOSIS WITH A VECTOR EXPRESSING RB2/p130

Publications (2)

Publication Number Publication Date
DE69929074D1 true DE69929074D1 (de) 2006-01-26
DE69929074T2 DE69929074T2 (de) 2006-08-10

Family

ID=22277147

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69929074T Expired - Fee Related DE69929074T2 (de) 1998-09-11 1999-09-10 Verwendung von einem rb2/p130 exprimierenden vektor zur verhinderung oder behandlung von restenose oder atherosklerotischen ablagerungen

Country Status (7)

Country Link
US (1) US6596698B1 (de)
EP (1) EP1119581B1 (de)
JP (1) JP4680385B2 (de)
AT (1) ATE313336T1 (de)
CA (1) CA2347178C (de)
DE (1) DE69929074T2 (de)
WO (1) WO2000015649A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
CA2362550C (en) 1999-02-22 2010-05-11 Georgetown University Antibody fragment-targeted immunoliposomes for systemic gene delivery
US9034329B2 (en) 1999-02-22 2015-05-19 Georgetown University Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof
US20040063090A1 (en) * 2001-01-05 2004-04-01 Claudio Pier Paolo Method for quantification of recombinant viruses
WO2004044161A2 (en) * 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
EP1594956A4 (de) 2003-02-03 2007-08-01 Fraunhofer Usa Inc System zur expression von genen in pflanzen
WO2005081905A2 (en) * 2004-02-20 2005-09-09 Fraunhofer Usa Inc. Systems and methods for clonal expression in plants
US7159408B2 (en) 2004-07-28 2007-01-09 Carrier Corporation Charge loss detection and prognostics for multi-modular split systems
EP2023897A4 (de) 2006-05-15 2013-04-03 Univ Georgetown Herstellung von antikörper- oder antikörperfragmentgezielten immunoliposomen zur systemischen verabreichung von therapeutischen oder diagnostischen wirkstoffen und verwendungen davon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element

Also Published As

Publication number Publication date
WO2000015649A9 (en) 2000-06-15
JP2002524568A (ja) 2002-08-06
DE69929074T2 (de) 2006-08-10
JP4680385B2 (ja) 2011-05-11
EP1119581A4 (de) 2002-07-10
CA2347178C (en) 2010-05-04
EP1119581B1 (de) 2005-12-21
ATE313336T1 (de) 2006-01-15
US6596698B1 (en) 2003-07-22
CA2347178A1 (en) 2000-03-23
WO2000015649A1 (en) 2000-03-23
EP1119581A1 (de) 2001-08-01

Similar Documents

Publication Publication Date Title
DE69920497D1 (de) Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
DE69929074D1 (de) Verwendung von einem rb2/p130 exprimierenden vektor zur verhinderung oder behandlung von restenose oder atherosklerotischen ablagerungen
DE69422052D1 (de) Vorrichtung zum erzeugen von elektroschocks optimaler dauer zur behandlung von herzarrhythmien
IT8123448A0 (it) Applicazione di rivestimenti metallici su un substrato, relativi prodotti e metodi.
ATE322290T1 (de) Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia
DE69533697D1 (de) ANTISENSE OLIGONUKLEOTIDMODULATION DER raf GENEXPRESSION
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
DE69722621D1 (de) Inhibierung von dns reparatur zur erhöhung der sensitivität für p53-vermittelte suppression
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
NO159484C (no) Fremgangsm te for behandling av vann, samt innretniremgangsm tens utfoerelse.
ZA979753B (en) Use of inhibitors of the activity of retinoic acid for treating sensitive skins and/or the acute damage induced by UV radiation.
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE69815580D1 (de) Verfahren zur Oxidation von Kohlenwasserstoffen, Alkoholen und/oder Ketonen
TR199802619T2 (xx) �ekilli ka��t helvalar �retmek i�in bir y�ntem.
DE3853641D1 (de) Schallerzeuger zur Behandlung eines Lebewesens mit fokussierten Schallwellen.
DE69315209D1 (de) Behandlung von Fleisch oder Fisch
ATE441701T1 (de) Zusammensetzung und verfahren zurhemmung von mikroorganismen
DE68912913D1 (de) Vorrichtung zur elektrolytischen Behandlung von metallischen Gegenständen.
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
ATE303158T1 (de) Verwendung von beta-interferon zur behandlung der restenose
DE58907597D1 (de) Verfahren zur Herstellung von Gusseisen mit Kugelgraphit und/oder Vermiculargraphit.
DE50003587D1 (de) Verbundelemente
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
ATE309337T1 (de) Kombination von genen zur regulierung der blühinduktion bei nutz- und zierpflanzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee